Protective Immunity against Ocular Herpes Infection and Disease Induced by Highly Immunogenic Self-Adjuvanting Glycoprotein D Lipopeptide Vaccines

Bettahi, Ilham; Nesburn, Anthony B.; Yoon, Susan; Zhang, Xiuli; Mohebbi, A.; Sue, Valerie; Vanderberg, A.; Wechsler, Steven L.; BenMohamed, Lbachir

doi:10.1167/iovs.07-0356

Cited by 39 publications

(43 citation statements)

References 68 publications

(115 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Heat-inactivated virus was made by heating a virus solution at 100°C for 5 min. HSV inactivation was confirmed by the inability to produce plaques when tested on Vero cells as previously described (11,52).…”

Section: Study Population From August 2003 To October 2007 We Screementioning

confidence: 99%

Gender-Dependent HLA-DR-Restricted Epitopes Identified from Herpes Simplex Virus Type 1 Glycoprotein D

Zhang

Castelli

Zhu

et al. 2008

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

Section: Study Population From August 2003 To October 2007 We Screementioning

confidence: 99%

Gender-Dependent HLA-DR-Restricted Epitopes Identified from Herpes Simplex Virus Type 1 Glycoprotein D

Zhang

Castelli

Zhu

et al. 2008

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

“…Conformational analysis of the gD 301-309 sequence confirmed the presence of a type I β-turn structure, which included the aspartate-proline-valine-glycine (DPVG) epitope core. 33 Moreover, previous studies indicated that the gD 301-309 epitope induced gD-specific responses and also elicited an immune response that conferred protection against lethal HSV-1 infection. 34 ).…”

Section: Identification Of Peptide Epitopesmentioning

confidence: 99%

Self-assembled or mixed peptide amphiphile micelles from Herpes simplex virus glycoproteins as potential immunomodulatory treatment

Accardo¹,

Vitiello²,

Tesauro³

et al. 2014

IJN

View full text Add to dashboard Cite

The use of micelle aggregates formed from peptide amphiphiles (PAs) as potential synthetic self-adjuvant vaccines to treat Herpes simplex virus (HSV) infection are reported here. The PAs were based on epitopes gB 409–505 and gD 301–309 , selected from HSV envelope glycoprotein B (gB) and glycoprotein D (gD), that had their N-terminus modified with hydrophobic moieties containing two C18 hydrocarbon chains. Pure and mixed micelles of gB and/or gD peptide epitopes were easily prepared after starting with the synthesis of corresponding PAs by solid phase methods. Structural characterization of the aggregates confirmed that they were sufficiently stable and compatible with in vivo use: critical micelle concentration values around 4.0 ⋅ 10 −7 mol ⋅ Kg −1 ; hydrodynamic radii (R H ) between 50–80 nm, and a zeta potential (ζ) around − 40 mV were found for all aggregates. The in vitro results indicate that both peptide epitopes and micelles, at 10 μM, triggered U937 and RAW 264.7 cells to release appreciable levels of cytokines. In particular, interleukin (IL)-23-, IL-6-, IL-8- or macrophage inflammatory protein (MIP)-2-, and tumor necrosis factor (TNF)-α-release increased considerably when cells were treated with the gB-micelles or gD-micelles compared with the production of the same cytokines when the stimulus was the single gB or gD peptide.

show abstract

“…But the strength of this protective immunity induced by these lipopeptides together with their safety need to be ascertained to combat ocular herpes infection and disease in humans [58].…”

Section: Recent Developments: Newer Drug Formulations and Vaccinationmentioning

confidence: 99%

Current Concepts in the Management of Herpes Simplex Anterior Segment Eye Disease

Reddy

Rapuano

2013

Curr Ophthalmol Rep

View full text Add to dashboard Cite

Herpes simplex virus-1 (HSV-1) infects the majority of the world's population during their lifetime. The prevalence of HSV primarily depends on geographic location, socioeconomic status, and age. HSV ocular disease rarely manifests as primary disease and most commonly as a recurrent disease. Recurrent HSV affects all the anterior segment structures in various clinical forms. In the cornea, HSV manifests as epithelial, stromal and endothelial disease. Depending on the structure involved, signs, symptoms and management options differ. Early diagnosis and prompt and appropriate management can lead to early resolution of the disease and maintenance of anatomic and functional integrity of ocular structures.

show abstract

Protective Immunity against Ocular Herpes Infection and Disease Induced by Highly Immunogenic Self-Adjuvanting Glycoprotein D Lipopeptide Vaccines

Cited by 39 publications

References 68 publications

Gender-Dependent HLA-DR-Restricted Epitopes Identified from Herpes Simplex Virus Type 1 Glycoprotein D

Gender-Dependent HLA-DR-Restricted Epitopes Identified from Herpes Simplex Virus Type 1 Glycoprotein D

Self-assembled or mixed peptide amphiphile micelles from Herpes simplex virus glycoproteins as potential immunomodulatory treatment

Current Concepts in the Management of Herpes Simplex Anterior Segment Eye Disease

Contact Info

Product

Resources

About